Our Mission
To improve the quality of genetic research and human healthcare by enabling cost-effective complete sequencing of relevant genes.
Uniquely, TLA enables targeted, complete, cost-effective Next Generation Sequencing
Cergentis provides services and kits for targeted NGS sequencing of any (trans)gene of interest
"TLA has proven to be a powerful technology for transgene integration site sequencing and for evaluation of structural changes in the transgene and/or integration site.”
Ludwig Maximilians University Munich
Dr. Nik Klymiuk - Molecular Animal Breeding and Biotechnology (Germany)
"Targeted Locus Amplification enables fast identification of new chromosomal rearrangements and genomic breakpoint sequences in human T-ALL and unraveled a higher complexity of chromosomal translocations of known T-ALL oncogenes as thus far appreciated.”
Ghent University
Prof. Dr. Pieter van Vlierberghe - Center for Medical Genetics (Belgium)
"TLA is a highly efficient method for mapping the insertion site of any transgene.”
Genentech
Dr. Søren Warming - Associate Director/Senior Scientist (San Francisco, CA, USA)
"We use TLA to sequence gene fusions and other rearrangements in genes of interest. We have been impressed by the quality of TLA and Cergentis’ work and are testing the use of identified breakpoint sequences as targets for personalised minimal residual disease tests.”
Princess Máxima Center for Pediatric Oncology
Dr. Roland Kuiper - Senior PI (Utrecht, The Netherlands)
"TLA outperforms traditional methods used in CHO cell line characterisation and provides higher resolution and sensitivity.”
Synthon
Dr. Stefanie Bartels - Project Leader - Cell Line Development (The Netherlands)
"Thank you so much. Data about the structural changes in our patient are very clear. Really powerful technology!”
University of Turin
Prof. Dr. Alfredo Brusco - Department of Medical Sciences (Italy)
"Cergentis quickly determined transgene insertion for three out of three lines along with providing information on deletions and rearrangements in chromosomal DNA at the site. The service was quick, accurate and reasonably priced, and reports were complete and helpful.”
Harvard University
Prof. Dr. Joshua Sanes - Department of Molecular and Cellular Biology (Cambridge, MA, USA)
"TLA analysis has proven to be very useful to quality control genetically engineered cell lines”
AstraZeneca
Dr. John Wiseman - Associate Director (Molndal, Sweden)
"Unknown translocation partners that drive expression of oncogenes as consequence of cryptic or previous unidentified chromosomal rearrangements were identified in T-cell leukemia patients using Targeted Locus Amplification.”
Princess Máxima Center for Pediatric Oncology
Dr. Jules Meijerink - Principal Investigator (Utrecht, The Netherlands)
To improve the quality of genetic research and human healthcare by enabling cost-effective complete sequencing of relevant genes.